MGNX$1.99
$1.9802
Chart
Performance
Key Stats
AI MGNX Summary
Powered by LiveAIAI Scoreboard
Powered by LiveAIOverall Analysis
NeutralMacroGenics exhibits mixed signals, with some positive fundamental indicators but significant recent underperformance and volatile technicals. Thematic potential in biotech is present but overshadowed by current financial and developmental challenges.
Thematic
MacroGenics operates in the biopharmaceutical sector, which has strong thematic tailwinds in cancer treatment. However, its specific pipeline and recent performance create uncertainty.
Fundamental
MacroGenics demonstrates revenue generation and gross profit, but consistently reports net losses and negative free cash flow. The balance sheet shows sufficient cash for operations but ongoing cash burn is a concern.
Technical
The stock has experienced significant volatility and a substantial decline over the past year, with current momentum indicators suggesting a mixed picture. Trading below key long-term moving averages is a concern.
| Factor | Score |
|---|---|
| Oncology Drug Development | 70 |
| Biotechnology Innovation | 75 |
| Market Competition | 50 |
| Regulatory Approvals | 40 |
| Partnerships & Collaborations | 65 |
| Factor | Score |
|---|---|
| Valuation | 60 |
| Profitability | 30 |
| Growth | 70 |
| Balance Sheet Health | 75 |
| Cash Flow | 25 |
| Factor | Score |
|---|---|
| Trend Analysis | 20 |
| Momentum | 60 |
| Moving Averages | 30 |
| Volume | 65 |
| Support & Resistance | 50 |
AI Investing Checklist
Powered by LiveAIBullish Points (7)
Recent Positive Momentum
The stock has shown strong recent performance, with a 5-day return of 11.04% and a 1-month return of 43.7%. This indicates positive investor sentiment and potential buying interest.
Strong Cash Position
As of Q4 2024, the company holds $182.84 million in cash and cash equivalents, significantly more than its total debt of $37.46 million. This robust liquidity provides a buffer against financial headwinds.
Bearish Points (7)
Negative Earnings Per Share (EPS) Trend
The company has consistently reported negative EPS on a TTM basis (-$0.88). While there have been some positive surprises, the overall trend indicates ongoing profitability challenges.
Significant Operating Losses
The company's operating income for Q4 2024 was -$110.58 million, and net income was -$66.97 million. This indicates substantial operating expenses and a need for revenue growth to achieve profitability.
Calendar
August 2025
4
Next Earnings Date
H: $0.38
A: $0.38
L: $0.38
H: 75.90M
A: 28.06M
L: 7.50M
Profile
MacroGenics, Inc., a clinical-stage biopharmaceutical company, discovers, develops, manufactures, and commercializes antibody-based therapeutics to treat cancer in the United States. The company's product pipeline includes lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4 for the treatment of mCRPC and docetaxel that is in phase 2 clinical trials, as well as for the treatment of platinum-resistant ovarian cancer and clear cell gynecologic cancer which has completed phase 1 clinical trial; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload; MGC028, an antibody-drug conjugates (ADC) that targets ADAM9 and delivers a novel TOP1i-based linker-payload for the treatment of solid tumors, which is in phase 1 clinical trials; MGC030, a ADC molecule for the treatment of solid tumors, which is in preclinical trials. It is also developing next generation T-cell engager programs. The company has collaborations with TerSera Therapeutics LLC; Incyte Corporation; and Gilead Sciences, Inc. MacroGenics, Inc. was incorporated in 2000 and is headquartered in Rockville, Maryland.
Seasonals
Price Target
4.20 USD
The 39 analysts offering 1 year price forecasts for MGNX have a max estimate of 8.00 and a min estimate of 2.00.
Debt Level and Coverage
Financial Position Analysis
Ownership
Capital Structure
Valuation - Summary
Valuation - Ratios
Revenue to Profit Conversion
Balance Sheet
Income Statement
Cash Flow
Related Companies
Powered by LiveAIWeight: 95
Clinical-stage biopharmaceutical company with a broad pipeline focused on engineered antibodies and cytokines, including bispecific antibodies and Fc-engineered antibodies, directly overlapping with MacroGenics' technology platforms in oncology.
Weight: 92
Develops bispecific antibodies and antibody-drug conjugates (ADCs) using proprietary platforms, directly competing with MacroGenics in the development of multi-specific and ADC therapeutics for cancer.
Weight: 90
Utilizes a cell-free protein synthesis platform to develop antibody-drug conjugates (ADCs) and bispecific antibodies, offering a similar, innovative approach to oncology drug discovery as MacroGenics.
Weight: 88
Pure-play antibody-drug conjugate (ADC) company with multiple clinical-stage assets, indicating a direct focus on a key technology area for MacroGenics in oncology.